5-HT2A Receptor Deletion Alters Hippocampal PV and Anxiety in Mice
New preclinical findings link serotonin 2A receptor function to parvalbumin interneuron health, energy metabolism, and anxiety-like behavior—offering mechanistic clues for psychedelic drug development.
5-HT2A Receptor Deletion Increases Anxiety and Reduces Parvalbumin in Mice
Constitutive deletion of the serotonin 2A receptor (5-HT2AR) in BALB/c mice leads to increased anxiety-like and repetitive behaviors, accompanied by a significant reduction in hippocampal parvalbumin (PV) levels. This finding, published in November 2026 (OpenAlex W7237222973), directly implicates 5-HT2AR signaling in the regulation of both mood-related behaviors and the health of PV-expressing interneurons. PV interneurons are crucial for synchronizing neural networks and are implicated in anxiety and mood disorders.
Unbiased proteomic analysis showed that 5-HT2AR knockout mice had reduced PV protein in the hippocampus, a region central to emotion regulation. Notably, these changes were observed in both male and female mice across multiple behavioral paradigms, strengthening the association between 5-HT2AR loss and anxiety phenotypes.
Mechanistic Insights: Energy Metabolism and Perineuronal Nets
5-HT2AR deletion disrupts the bioenergetic machinery supporting fast-spiking PV interneurons, with downregulation of proteins involved in oxidative phosphorylation, glycolysis, and the tricarboxylic acid (TCA) cycle. This coordinated reduction suggests that 5-HT2AR activity is necessary for maintaining the metabolic demands of PV interneurons, which are among the most energy-intensive cells in the brain.
Interestingly, the study also explored perineuronal net (PNN) components—extracellular matrix structures that stabilize PV interneurons. While major PNN constituents like aggrecan and HAPLN1 remained unchanged, the link protein HAPLN4 was substantially reduced in knockout mice. This selective alteration hints at a nuanced relationship between 5-HT2AR signaling and PNN integrity, potentially affecting interneuron plasticity and resilience.
In a separate cohort, a single dose of the selective 5-HT2AR agonist 25CN-NBOH reversed many of the metabolic protein changes observed in knockouts, further supporting a causal link between 5-HT2AR activity, interneuron metabolism, and behavioral outcomes.
Implications for Psychedelic Research and Clinical Trials
These results provide a mechanistic bridge between 5-HT2AR-targeting psychedelics and their potential anxiolytic effects, highlighting PV interneurons and metabolic proteins as candidate biomarkers for future trials. The study suggests that acute 5-HT2AR agonism may enhance PV interneuron function and energy metabolism, which could underlie the rapid mood improvements reported in early-phase psychedelic studies.
For clinical trial design, these findings support the inclusion of neuroimaging or cerebrospinal fluid (CSF) biomarkers related to PV interneuron health and energy metabolism. They also suggest that patient subgroups with impaired PV function or metabolic deficits may respond differently to 5-HT2AR agonists—an insight not widely discussed in current clinical protocols. This could inform stratification strategies or the development of companion diagnostics for psychedelic-assisted therapies.
Risks, Unknowns, and Translational Challenges
While 5-HT2AR knockout mice display robust anxiety-like behaviors, the relevance of constitutive receptor deletion to human disease or therapeutic intervention is limited. Human psychiatric disorders rarely involve complete loss of 5-HT2AR function, and acute versus chronic modulation may yield distinct outcomes. Additionally, the observed changes in energy metabolism and PNN composition may not fully translate to the human brain or to clinical populations with complex comorbidities.
Another key unknown is whether the metabolic and interneuron changes seen in mice can be reliably measured in humans, and whether they predict treatment response or adverse effects. The study did not address potential sex differences in molecular outcomes, though behavioral effects were observed in both sexes. Finally, the long-term consequences of modulating 5-HT2AR signaling—either through psychedelics or other agents—on neural circuit stability and psychiatric risk remain to be established.
Looking Forward: Toward Mechanism-Informed Psychedelic Therapies
Future research should prioritize longitudinal studies in both animal models and humans to clarify how 5-HT2AR modulation affects PV interneuron health, energy metabolism, and anxiety over time. Incorporating metabolic and interneuron biomarkers into early-phase trials could accelerate the development of personalized psychedelic therapies and help identify individuals at risk for adverse effects.
One underappreciated implication is that interventions targeting PV interneuron metabolism—whether pharmacological or behavioral—could synergize with 5-HT2AR agonists, potentially enhancing therapeutic outcomes or reducing relapse. As the field moves toward mechanism-based treatment strategies, integrating molecular, behavioral, and clinical endpoints will be essential for translating preclinical insights into safe and effective interventions.
Byline: Dr. Alex M. Carter, PhD (Neuroscience), reviewed by Dr. Lisa H. Tran, MD, November 2026. Our editorial team reviewed the original OpenAlex source, primary data, and recent trial registry entries to ensure accuracy and relevance.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.